Enfusion, Inc. (NYSE:ENFN) Given Average Rating of “Reduce” by Brokerages

Enfusion, Inc. (NYSE:ENFN) has been given an average rating of “Reduce” by the six research firms that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $9.33.

Several analysts have issued reports on the company. The Goldman Sachs Group cut Enfusion from a “neutral” rating to a “sell” rating and cut their price objective for the company from $9.00 to $8.00 in a research note on Wednesday, February 28th. Bank of America raised their price objective on Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a research note on Wednesday, March 13th. Finally, JPMorgan Chase & Co. downgraded shares of Enfusion from a “neutral” rating to an “underweight” rating and decreased their price objective for the stock from $11.00 to $9.00 in a report on Tuesday, January 30th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ENFN. Envestnet Asset Management Inc. acquired a new stake in shares of Enfusion in the first quarter valued at $128,000. Bank of New York Mellon Corp boosted its holdings in Enfusion by 1,435.5% during the first quarter. Bank of New York Mellon Corp now owns 762,883 shares of the company’s stock worth $9,704,000 after buying an additional 713,201 shares in the last quarter. Citigroup Inc. grew its position in Enfusion by 24.2% in the first quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock worth $91,000 after buying an additional 1,390 shares during the last quarter. MetLife Investment Management LLC grew its position in Enfusion by 55.4% in the first quarter. MetLife Investment Management LLC now owns 14,206 shares of the company’s stock worth $181,000 after buying an additional 5,065 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Enfusion by 33.6% in the first quarter. Rhumbline Advisers now owns 21,723 shares of the company’s stock valued at $276,000 after buying an additional 5,468 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors.

Enfusion Trading Down 2.1 %

ENFN stock opened at $9.11 on Friday. The firm has a 50 day simple moving average of $9.06 and a 200-day simple moving average of $9.12. The company has a market capitalization of $1.17 billion, a P/E ratio of 113.83, a PEG ratio of 2.70 and a beta of 1.00. Enfusion has a twelve month low of $7.37 and a twelve month high of $11.56.

Enfusion (NYSE:ENFN) last announced its quarterly earnings data on Tuesday, March 12th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). The company had revenue of $46.49 million for the quarter, compared to analyst estimates of $45.56 million. Enfusion had a return on equity of 10.30% and a net margin of 3.45%. On average, research analysts predict that Enfusion will post 0.07 EPS for the current year.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.